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Cell-cycle arrest, apoptosis, and senescence are
widely accepted as the major mechanisms by which
p53 inhibits tumor formation.Nevertheless, it remains
unclear whether they are the rate-limiting steps in
tumor suppression. Here, we have generated mice
bearing lysine to arginine mutations at one
(p53K117R) or three (p533KR; K117R+K161R+K162R)
of p53 acetylation sites. Althoughp53K117R/K117R cells
are competent for p53-mediated cell-cycle arrest
and senescence, but not apoptosis, all three of
these processes are ablated in p533KR/3KR cells.
Surprisingly, unlike p53 null mice, which rapidly
succumb to spontaneous thymic lymphomas, early-
onset tumor formation does not occur in either
p53K117R/K117R or p533KR/3KR animals. Notably,
p533KR retains the ability to regulate energy metabo-
lism and reactive oxygen species production. These
findings underscore the crucial role of acetylation
in differentially modulating p53 responses and
suggest that unconventional activities of p53, such
as metabolic regulation and antioxidant function,
are critical for suppression of early-onset sponta-
neous tumorigenesis.INTRODUCTION
The p53 tumor suppressor regulates multiple signaling pathways
triggered by diverse cellular stresses, including DNA damage,
abnormal oncogenic events, loss of normal cell contacts, and
hypoxia, as well as some normal cellular processes (Vousden
and Prives, 2009; Feng and Levine, 2010). Although the molec-
ular mechanism of p53-mediated tumor suppression is not
completely understood, it is widely accepted that tumor cell
growth can be inhibited by p53-mediated cell-cycle arrest,
apoptotic cell death, and/or cellular senescence. p53 is regu-
lated by an exquisite network of fine-tuning mechanisms that
ensure proper responses to the various stress signals encoun-tered by cells. In broad terms, p53 activities are controlled
via protein levels, coactivator/corepressor recruitment, and
a diverse array of posttranslational modifications that include
acetylation, ubiquitination, phosphorylation, methylation, SU-
MOylation, and neddylation (Kruse and Gu, 2009).
Numerous studies demonstrate that nonhistone protein
acetylation is critically involved in regulating diverse cellular
processes such as transcription, protein folding, and cellular
metabolism (Kim et al., 2006; Choudhary et al., 2009; Wang
et al., 2010; Zhao et al., 2010). p53 was the first nonhistone
protein shown to be regulated functionally by acetylation and
deacetylation (Gu and Roeder, 1997; Luo et al., 2000, 2001;
Vaziri et al., 2001), and subsequent work has established that
acetylation plays a key role in controlling promoter-specific
activation of p53 targets during stress responses (Berger,
2010; Kruse and Gu, 2009). The major acetylation sites of
human p53 include two lysine residues (K120 and K164) within
the DNA-binding domain and a cluster of six lysines with the
C-terminal domain. We and others recently showed that p53
is acetylated at K120 by Tip60/MOF (Sykes et al., 2006; Tang
et al., 2006; Li et al., 2009), whereas K164 is acetylated by
CBP and p300, but not Tip60/MOF (Tang et al., 2008). Both sites
are mutated in human tumors and well conserved in all species
known to encode p53. Interestingly, K120 acetylation is crucial
for p53-mediated apoptosis but has no obvious effect on
cell-cycle arrest, whereas simultaneous loss of acetylation at
all major sites abolishes the ability of p53 to induce both
cell-cycle arrest and apoptosis (Tang et al., 2008), suggesting
that acetylation is essential for both p53-mediated processes.
However, the role of acetylation in the most critical aspect of
p53 function, its ability to suppress tumor formation, has not
been addressed.
To investigate whether p53 acetylation is important for tumor
suppression, we generated p53 mutant mice (p53K117R/K117R)
in which K117 (K120 in human) is replaced by arginine. In these
animals, p53-mediated apoptosis is completely abrogated, but
p53-dependent cell-cycle arrest and senescence remain intact.
We also established mice (p533KR/3KR) in which the three acety-
lation sites of the DNA-binding domain (K117, K161, K162) were
simultaneously replaced by arginine. Significantly, loss of acety-
lation at these three sites completely abolished the ability of p53
to mediate cell-cycle arrest, apoptosis, and senescence in vivo.Cell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc. 1269
To evaluate whether these p53-dependent processes are
required for tumor suppression, we monitored tumor formation
in cohorts of p53 acetylation-deficient mice. Although p53 null
mice rapidly develop spontaneous thymic lymphomas (Done-
hower et al., 1992; Jacks et al., 1994; Lozano, 2010), neither
p53K117R/K117R nor p533KR/3KR mice are prone to early-onset
tumorigenesis. Because tumor suppression can be mediated
by a p53 polypeptide (e.g., p533KR) that lacks the ability to induce
p53-dependent cell-cycle arrest, apoptosis, and senescence,
these results indicate that other aspects of p53 function are suffi-
cient to suppress tumor formation. Strikingly, the p533KR mutant
retains the capacity to inhibit glycolysis and reduce the levels of
reactive oxygen species (ROS). These findings suggest that
current views regarding the mechanism of p53-mediated tumor
suppression should be reconsidered.
RESULTS
Generation of p53K117R Knockin Mice
To elucidate the physiological functions of p53 acetylation,
we first used mass spectrometric (MS/MS) analysis of mouse
p53 protein to confirm that lysine 117 (K117) (corresponding
human lysine 120) is indeed acetylated (see Figure S1 available
online). Mouse embryonic stem (ES) cells were then electropo-
rated with a knockin-targeting construct designed to replace
lysine codon 117 with an arginine codon (K117R) (Figure S2A).
Properly targeted G418-resistant clones were identified by
Southern analysis (Figure S2B), and two independent clones
were injected into C57BL/6 blastocysts to achieve germline
transmission of the p53K117R allele. The heterozygous F1 mice
were then bred with Rosa26-Cre transgenic mice to delete
the LoxP-flanked neomycin resistance gene (neo) from the
targeted allele. The resultant neo-deleted heterozygous
p53K117R/+ mice were intercrossed, and their progeny was
genotyped by PCR (Figure S2C). Of note, homozygous
p53K117R/K117R mice were obtained at the expected Mendelian
ratio (Figure S2D) and displayed no apparent developmental
abnormalities. Expression of the mutant gene product was
confirmed by sequence analysis of p53 cDNAs from
p53K117R/K117R cells (Figure S2E).
K117R Mutation Has No Effect on p53 Stabilization
but Completely Abolishes p53-Mediated Apoptosis
Previous studies in human cell lines indicate that K120 acetyla-
tion is crucial for apoptosis but has no obvious effect on p53
protein stability or p53-mediated cell-cycle arrest (Sykes et al.,
2006; Tang et al., 2006). To ascertain whether K117 acetylation
regulates p53 apoptotic function similarly in mice, we analyzed
p53-dependent apoptosis in p53K117R/K117R thymocytes
subjected to ionizing radiation (IR). The levels of p53 protein
were induced in a similar fashion by IR in p53K117R/K117R and
wild-type (WT) thymocytes (Figure 1A), and IR-induced p53
phosphorylation (p-p53) remained intact. Although IR-induced
transactivation of p21, a p53 target gene required for cell-cycle
arrest, was observed in p53K117R/K117R thymocytes, IR induction
of PUMA, an apoptotic p53 target, was completely abrogated.
Moreover, immunostaining for the active form of caspase 3
revealed that IR-induced apoptosis was also abolished in1270 Cell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc.p53K117R/K117R thymocytes (Figure 1B). To corroborate these
findings, thymocytes were isolated from both p53K117R/K117R
and WT mice 4 hr after irradiation and stained with annexin
V-FITC. FACS analysis showed that IR-induced apoptosis was
virtually abrogated in p53K117R/K117R thymocytes (Figures 1C
and 1D). To examine whether these effects are cell-type specific,
we also examined apoptotic responses in other tissues sensitive
to DNA damage. As shown in Figure 1E, K117R mutation
completely blocked the apoptotic response in testis, intestine,
and spleen. Detailed analysis again showed that p53-mediated
activation of proapoptotic target genes and p53-dependent
apoptosis were ablated in p53K117R/K117R spleens (Figure S3).
These data indicate that K117 acetylation is required for p53-
dependent apoptosis in vivo.
p53-Dependent Cell-Cycle Arrest and Senescence
Remain Intact in p53K117R/K117R MEFs
To determine whether the K117R mutation affects p53-
dependent cell-cycle arrest and senescence, we compared the
response of p53K117R/K117R and WT mouse embryonic fibro-
blasts (MEFs) to treatment with the genotoxic agent doxorubicin
(Dox). As shown in Figure 2A, stabilization and phosphorylation
of p53K117R polypeptides occurred normally in response to
Dox. Consistent with results obtained in mouse tissues (Fig-
ure 1A), p53-mediated transactivation of PUMA, but not p21
or Mdm2, was completely abrogated in p53K117R/K117R MEFs
(Figure 2A). Moreover, p53K117R/K117R MEFs were also defective
for induction of other known proapoptotic p53 target genes such
as NOXA and DR5 (Figure 2B). To examine whether the K117R
mutation affects p53-mediated growth arrest, p53K117R/K117R
andWTMEFs were pulse labeled for BrdU, fixed in 70% ethanol,
and double stained with anti-BrdU antibody and DAPI. As shown
in Figure 2C, IR treatment reduced the levels of BrdU incorpora-
tion to a comparable degree in both p53K117R/K117R and WT
MEFs (Figures 2C and 2D). In addition we compared the growth
and senescence of WT and p53K117R/K117R MEFs following
a standard 3T3 proliferation protocol. As expected, the expres-
sion levels of p53, p21, and Arf increased gradually upon
passage of both WT and p53K117R MEFs (Figure 2E). Although
p53K117R/K117R cells proliferated slightly faster than WT MEFs
(Figure S4), both reached senescence similarly at passage 7
(Figure 2F). Together, these data suggest that the p53K117R
mutant retains its ability to induce both cell-cycle arrest and
senescence in vivo.
Loss of Acetylation at Three Sites of Mouse p53
Abrogates Transcriptional Induction of Both p21
and PUMA
Although K117 acetylation is required for the p53-mediated
apoptotic response in vivo (Figure 1), we observed no obvious
differences between p53K117R/K117R and p53 WT cells with
respect to either cell-cycle arrest or senescence. Notably, our
recent study showed that elimination of multiple acetylation sites
on human p53 abrogates both the growth arrest and apoptosis
functions of p53 (Tang et al., 2008). To explore this possibility,
we sought to generate amutantmouse that would also be defec-
tive for p53-dependent cell-cycle arrest and senescence. Our
previous studies indicated that K164 acetylation of human p53
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Figure 1. p53K117R Activates p21 Normally but Completely Abrogates Activation of Proapoptotic Target Genes
(A) Western blot analysis of the thymus of p53+/+, p53K117R/K117R, and p53/ mice. Mice were either untreated or exposed to 12.5 Gy of g irradiation, 4 hr later;
thymocytes were isolated and analyzed for the expression of p53, phospho-p53, and p21, PUMA, cleaved caspase 3 and b-actin.
(B) Representative immunohistochemical (IHC) staining of thymi from p53+/+ and p53K117R/K117R mice for cleaved caspase 3. Eight-week-old mice were either
untreated or exposed to 5 Gy of g irradiation. Four hours later, thymi from these mice were fixed overnight then processed, paraffin embedded, sectioned, and
stained with anti-mouse cleaved caspase 3 antibodies according to the standard protocol.
(C) In vivo apoptotic analysis of p53+/+ and p53K117R/K117R mice after 5 Gy of g irradiation. Mice were treated as described in (B), then single-cell suspension of
thymocytes from mice was prepared and stained with annexin V-FITC for FACS analysis.
(D) Quantification of apoptosis in vivo represented by annexin V-positive thymocytes. Error bars represent averages ± SD from at least three mice for each
genotype.
(E) Representative cleaved caspase 3 immunohistochemical staining images showing apoptotic cells in the spleen, testis, and small intestine of p53+/+ and
p53K117R/K117R mice. Eight-week-old mice were either untreated or exposed to 12.5 Gy of g irradiation, then tissues were collected 4 hr later and processed as
described in (B).
See also Figures S1, S2, and S3.
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Figure 2. p53K117R/K117R MEFs Retain Intact Cell-Cycle Checkpoint and Cellular Senescence Function in Response to DNA Damage
(A) Western blot analysis of Mdm2, p53, phosphorylated p53, PUMA, and p21 in p53+/+ and p53K117R/K117R MEFs either left untreated or treated with 1.0 mMDox
for 8 hr; b-actin was used as a loading control.
(B) Quantitative real-time PCR analysis of Mdm2, p21, PUMA, Killer/DR5, and Noxa mRNA in p53+/+ and p53K117R/K117R MEFs either untreated or treated with
1.0 mM Dox for 8 hr. Data shown are the relative amounts of specific mRNA normalized first to b-actin and then to the untreated WT sample values from three
independent experiments with different MEF lines. Results are reported as average ± SEM.
(C) Cell growth arrest analysis of p53+/+ and p53K117R/K117R MEFs either left untreated or exposed to 5 Gy of g irradiation. Twenty-three hours after irradiation,
MEFs were pulsed with 10 mM BrdU for 45 min, and then cells were fixed and processed for immunofluorescence analysis for BrdU (green). The nuclei were
stained with DAPI (blue).
(D) Quantification of BrdU labeling of p53+/+ and p53K117R/K117RMEFs irradiated with 5 and 10 Gy. Error bars represent ±SD from three independent experiments.
(E) Western blot analysis of p53+/+ and p53K117R/K117R MEFs at different passages cultured according to a 3T3 protocol for the expression of p53, Arf, and p21.
(F) Senescence-associated b-galactosidase staining of p53+/+ and p53K117R/K117R MEFs cultured according to a 3T3 protocol. MEFs at indicated passages were
fixed and stained for b-galactosidase activity as described in the Extended Experimental Procedures.
See also Figure S4.
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(corresponding to K161 of mouse p53) is critical for p53-
mediated cell-cycle arrest (Tang et al., 2008). Interestingly, as
shown in Figure 3A, both K161 and K162 of mouse p53
(corresponding to K164 and Q165 of human p53) are evolution-
arily conserved in all species, with the exception of Q165 in
human. Moreover, mass spectrometry analysis of mouse p53
revealed that both K161 and K162 are acetylated in vivo
(Figure 3B). Therefore, we generated an expression plasmid
encoding a mouse p53 mutant (p533KR) in which all three acety-
lation sites (K117, K161, and K162) are replaced by arginine. As
expected, expression of WT mouse p53 in p53 null human
H1299 cells induced transcription of both p21 and PUMA
(lane 2, Figure 3C). Moreover, consistent with the data from
p53K117R/K117R mice (Figure 2A), expression of p53K117R induced
p21, but not PUMA, transcription (lane 4). Strikingly, loss of
acetylation at all three sites (K117R, K161R, and K162R:
p533KR) completely abolished the induction of both p21 and
PUMA (Figure 2A, lane 3). Because the three mutated residues
all reside within the DNA-binding domain, we examined the
sequence-specific DNA-binding properties of p533KR in a chro-
matin immunoprecipitation (ChIP) assay. As shown in Figure 3D,
the DNA-binding activities of theWT and p533KR mutant forms of
mouse p53 were indistinguishable at a number of p53 target
promoters, including p21, PUMA, and Mdm2. Moreover,
p533KR readily induced expression of endogenous Mdm2
(lane 3, Figure 3C). Thus, we have identified a mouse p53mutant
(p533KR) that retains its ability to bind DNA and activate RNA
transcription but is likely defective for both p53-dependent
cell-cycle arrest and apoptosis.
p53-Mediated Cell-Cycle Arrest and Apoptosis Are
Abrogated in p533KR/3KR Mice
To elucidate the role of p53 acetylation in vivo, we used a similar
knockin-targeting strategy to introduce a p533KR allele into the
germline of mice (Figures S5A and S5B). Upon intercrossing
p533KR/+ heterozygotes, viable p533KR/3KR homozygous mice
were obtained at normal Mendelian ratios (Figures S5C and
S5D), and expression of the mutated p533KR allele was
confirmed by sequence analysis of cDNA from p533KR/3KR cells
(Figure S5E).
To examine p533KR-mediated function in vivo, we analyzed
p53-dependent apoptosis in p533KR/3KR thymocytes subjected
to IR. As expected, apoptosis was completely abrogated in
p533KR/3KR thymocytes (Figures 4A and 4B). To test whether
the p533KR mutation affects cell-cycle arrest, MEFs from embry-
onic day 13.5 were treated with Dox. As shown in Figure 4C, Dox
induced the stabilization and phosphorylation of p53 polypep-
tides to a comparable degree in p533KR/3KR and WT MEFs. In
accordance with results obtained using exogenous p53 expres-
sion (Figures 3C and 3D), Dox inducedMdm2 expression in both
p533KR/3KR and WT cells (albeit to a slightly lesser degree in
p533KR/3KR MEFs), whereas p21 and PUMA induction was
specifically ablated in p533KR/KR MEFs (Figure 4C). Similar
results were also obtained when p53-mediated responses
were examined under different types of stress conditions such
as etoposide, UV, and oxidative stress (Figures S6A–S6C).
Moreover, by using BrdU incorporation analysis, we found that
p533KR/3KR cells were defective for IR-induced arrest of cellproliferation (Figures 4D and S6D). Consistent with these obser-
vations, p53 protein levels were induced to a similar degree in
thymocytes from both WT and p533KR/3KR mice (Figure 4E),
whereas IR induction of p21 and PUMA transcription was
completely abrogated (Figure 4E). Moreover, to exclude the
possibility that the mutant cells die with slower kinetics, we
compared the levels of apoptosis induced by DNA damage in
p53-WT, p53K117R/K117R, p533KR/3KR, and p53 null mice. To this
end, p53-WT, p53K117R/K117R, p533KR/3KR, and p53 null mice
were treated with 12.5 Gy of g-radiation, and thymocytes
isolated from these mice at different time points after irradiation
(4, 8, and 24 hr) were analyzed for levels of apoptosis. As shown
in Figure 4F, the active form of caspase 3 was readily detected in
p53-WT mice at 4 and 8 hr after irradiation, indicating strong
IR-induced apoptosis under these conditions. In contrast, signif-
icant apoptosis was not observed in thymocytes isolated from
p53K117R/K117R, p533KR/3KR, or p53 null mice at any time point
after g-radiation.
Finally, to confirm whether p533KR is also defective for induc-
tion of other p53 target genes involved in cell-cycle arrest and
apoptosis, mRNA levels inWT andmutantMEFs were compared
by quantitative real-time RT-PCR. Significantly, none of the key
p53 targets involved in cell-cycle arrest (i.e., p21, 14-3- s, cyclin
G1/ccng1, and GADD45) or apoptosis (Bax, PUMA, NOXA, and
DR5) was induced by Dox in p533KR cells (Figures 5A and 5B).
Indeed, the expression levels of these target genes were virtually
indistinguishable in p533KRmutant cells and p53 null cells. Taken
together, these data indicate that the p533KRmutation abrogates
both p53-mediated cell-cycle arrest and apoptosis without
affecting either genotoxin-induced p53 stabilization or transacti-
vation of certain target genes such as Mdm2.
The p533KR/3KR Mutant Fails to Induce p53-Dependent
Senescence
In addition to cell-cycle arrest and apoptosis, numerous studies
have identified senescence as an alternative mechanism of
p53-mediated tumor suppression. In this regard we found that
Dox-induced transactivation of several p53 target genes,
including PAI-1 and PML, was also defective in p533KR/3KR
cells (Figures S7A and S7B). Therefore, we examined whether
p533KR/3KR MEFs are competent to undergo p53-dependent
cellular senescence. As shown in Figure 5C, p533KR/3KR MEFs
proliferated slightly slower than p53/ MEFs but dramatically
faster than WT MEFs. As expected, WT MEFs reached
senescence around passage 7; in contrast both p53/ and
p533KR/3KR MEFs continued to proliferate and showed no
evidence of senescence (Figure 5D). Notably, p53 and Arf
transcription was gradually induced on passage of p533KR/3KR
MEFs, similar to p53 null cells, but induction of p21 expression
was not observed in p533KR/3KR MEFs (Figures 5E and 5F).
In addition we examined oncogene-induced senescence in
these cells. As expected, very high levels of senescence were
observed in p53-WT-MEF cells upon oncogene (H-ras)
expression (Figures S7C and S7D); in contrast we were unable
to detect senescence of either p53-3KR or p53 null cells
under these conditions. Taken together, these data demon-
strate that p533KR/3KR cells fail to undergo p53-dependent
senescence.Cell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc. 1273
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Figure 3. Loss of Acetylation Sites at K117, K161, and K162 of Mouse p53 Abolishes the Activation of p21 and PUMA
(A) Schematic representation of themouse p53 protein with threemutated acetylation sites indicated and alignment of the K117, K161, and K162 flanking regions
of the mouse p53 with those of other species. The conserved lysines were highlighted in red, and Q165 of human p53 highlighted in blue is evolutionarily
reminiscent of acetylated K. The following abbreviations are used: h, human; m, mouse; c, chicken; x, Xenopus; and z, zebrafish.
(B) Mass spectrometry analysis of tryptic mouse p53 peptides containing K161 and K162. The fragmentation spectrum of 156AMoxAIYKacK
162 and 162 Kac
SQHMoxTEVVR
171 revealed the presence of peptides with acetylation at K161 and K162, respectively. The protein was prepared as described in the Experimental
Procedures. Inset shows the high-resolution precursor ion mass. The label ‘‘D’’ designates ‘‘b’’ or ‘‘y’’ ions with water and/or ammonia loss. ‘‘Kac’’ and ‘‘Mox’’
designate acetyllysine and oxidized methionine, respectively. Neutral loss of sulfenic acid from oxidized methionine was indicated as ‘‘64.’’
(C) Western blot analysis of p53,Mdm2, PUMA, and p21 in H1299 cells transfected with plasmids expressingmouseWT p53, p53-K117R, and p53-3KRmutants.
b-actin was used as a loading control.
(D) ChIP assay for the binding of p53 or p53-3KR mutant to the consensus sites in the p21, PUMA, andMdm2 promoters. H1299 cells transfected with plasmid
DNA-expressing mouse p53WT and p53-3KR mutant were treated with 1% formaldehyde for 10 min and processed for ChIP analysis. The occupancy of p53 or
p53-3KR of the p21, PUMA, and Mdm2 promoters was detected by PCR-agarose gel electrophoresis. IgG antibody serves as a negative control. Ctrl is an
abbreviation for control vector.
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Figure 4. p533KR Mutation Severely Abrogates the p53-Mediated Cell-Cycle Arrest and Apoptotic Cell Death
(A) Analysis of apoptosis in vivo for p53+/+ and p533KR/3KRmice. Mice were either untreated or exposed to 5 Gy of g irradiation, and then thymocytes were isolated
and stained with annexin V-FITC for FACS analysis.
(B) Annexin V-positive cells representing apoptotic thymocytes are quantified in (A). Data are shown as average ± SD from at least three mice for each genotype.
(C) Western blot analysis of Mdm2, p53, phosphorylated p53, PUMA, and p21 in p53+/+ and p533KR/3KR and p53/ MEFs either untreated or treated with
0.2 mg/ml Dox for 2, 4, and 8 hr. b-actin serves as a loading control.
(D) Cell-cycle arrest analysis of p53+/+ and p533KR/3KR MEFs either left untreated or exposed to 5 or 10 Gy of g irradiation. Twenty-three hours after irradiation,
MEFs were pulsed with 10 mM BrdU for 45 min, and then cells were fixed and processed for immunofluorescence analysis for BrdU. BrdU-positive cells rep-
resenting cells in S phase of cell cycle during BrdU incorporation after 5 or 10 Gy of g irradiation are quantified. Values shown are the averages ± SD of three
independent replicates.
(E) Immunoblot assays of p53, phospho-p53, PUMA, p21, cleaved caspase 3, and b-actin protein in the lysates prepared from the thymus of p53+/+, p533KR/3KR,
and p53/ mice 4 hr after 12.5 Gy of g irradiation.
(F) Western blot analysis of apoptosis in the thymus of p53+/+, p53K117R/K117R, p533KR/3KR, and p53/ mice upon DNA damage treatment. Mice were either
untreated or exposed to 12.5 Gy of g irradiation; thymocytes were isolated at different time points after irradiation and analyzed for the level of cleaved caspase 3.
b-actin was used as a loading control.
See also Figures S5 and S6.
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Figure 5. p533KR Loses Its Ability to Induce Cellular Senescence in p533KR/3KR MEFs
(A and B) Quantitative real-time PCR analysis of indicated mRNAs in p53+/+, p533KR/3KR, and p53/MEFs either untreated or treated with 0.2 mg/ml Dox for 8 hr.
Results shown are the relative amount of specific mRNA normalized first to b-actin and then to the untreated WT sample values from three independent
experiments with different MEF lines. Error bars represent ±SEM.
(C) Cell growth rate analysis of p53+/+, p533KR/3KR, and p53/MEFs. A total of 33 104 MEFs of different genotypes were seeded into 6-well plates at day 0 and
counted daily.
(D) Images of senescence-associated b-galactosidase staining of p53+/+ and p533KR/3KR MEFs at different passages cultured according to the 3T3 protocol.
MEFs at indicated passages were fixed and stained for b-galactosidase activity.
(E and F) Immunoblot analysis of p53, Arf, and p21 in p533KR/3KR (E) and p53/ (F) MEFs at indicated passages cultured according to the 3T3 protocol. b-actin
serves as a loading control.
See also Figure S7.
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p533KR/3KR Mice Do Not Succumb to the Early-Onset
Spontaneous Tumor Formation Commonly Observed
in p53 Null Mice
Although p533KR polypeptides retain the ability to bind DNA in
a sequence-specific fashion and transactivate expression of
the Mdm2 promoter, p533KR/3KR cells are defective for
p53-dependent cell-cycle arrest, apoptosis, and senescence.
Therefore, to ascertain whether any of these canonical p53
functions are required for tumor suppression, we compared
spontaneous tumor formation in cohorts of p53 WT (p53+/+),
null (p53/), and mutant (p53K117R/K117R and p533KR/3KR) mice.
In accord with published data by Donehower et al. (1992), Jacks
et al. (1994), and Lozano (2010), p53 null mice rapidly developed
spontaneous tumors, primarily thymic lymphomas, and most
died by 6 months of age. Although K117 acetylation is required
for the p53-mediated apoptotic response in vivo, we observed
no differences between p53K117R/K117R and WT mice with
respect to either normal development or spontaneous tumor
formation (Figure 6A). These results suggest that other functions
of p53 (e.g., cell-cycle arrest and/or senescence) are sufficient
to prevent early-onset spontaneous tumor formation. However,
most p533KR/3KR animals remained healthy up to at least
16 months of age. Thus, despite their inability to mediate
p53-dependent cell-cycle arrest, apoptosis, or senescence,
none of the p533KR/3KR mice succumbed to early-onset sponta-
neous tumors (Figure 6A). Indeed, only 3 of the 27 p533KR/3KR
mice developed tumors (Figure 6A), and sequence analysis
uncovered de novo mutations of the p533KR gene in the tumor
tissues of these 3 p533KR/3KRmice (Figure S7E), further validating
that p53-3KR retains its function as a tumor suppressor. These
data indicate that the combined loss of p53-mediated cell-cycle
arrest, senescence, and apoptosis is not sufficient to abrogate
the tumor suppression activity of p53.
p533KR Retains Its Ability to Regulate the Expression
of Metabolic p53 Target Genes
Cell-cycle arrest, senescence, and apoptosis are widely viewed
as the major mechanisms of p53-mediated tumor suppression;
yet, our data suggest that these classical p53 responses are
not essential for tumor suppression. Thus, other p53 functions,
particularly those retained by p533KR, may be more relevant to
suppression of early-onset tumorigenesis. To explore this possi-
bility, we examined p533KR-mediated transcriptional activation in
a panel of p53 target genes implicated in unconventional func-
tions of p53. Notably, quantitative real-time RT-PCR revealed
that the transcription of two known p53 target genes involved
in metabolic regulation, GLS2 and TIGAR (Hu et al., 2010; Suzuki
et al., 2010; Bensaad et al., 2006), was fully induced by Dox in
p533KR/3KR cells (Figure 6B). GLS2 encodes a mitochondrial
glutaminase that modulates mitochondrial respiration and ATP
generation by catalyzing the hydrolysis of glutamine to gluta-
mate, whereas TIGAR encodes a fructose bisphosphatase that
downregulates glycolysis by reducing cellular levels of fruc-
tose-2, 6,-bisphosphate. Further analysis showed that the
steady-state levels of GLS2 and TIGAR proteins were induced
by stress in both WT and p533KR/3KR MEFs, but not in p53/
cells (Figure 6C). To validate the p53 acetylation status in these
cells, p53+/+ and p533KR/3KR MEFs were first treated with0.2 mg/ml Dox for 8 hr and were then processed for immunopre-
cipitation analysis. Cell lysates were immunoprecipitated with
anti-AcK120-p53, anti-AcK164-p53, or anti-AcK CT-p53 anti-
bodies and blotted with anti-p53 (CM5) antibody. As expected,
acetylation of p53 at each of these sites was readily induced
by DNA damage in WT MEFs (lane 4, Figure 6D). In p533KR/3KR
MEFs, however, damage-induced acetylation of the C-terminal
lysines was retained, but no detectable acetylation was
observed at either K117 or K161 (Figure 6D, lane 6). Likewise,
K117 acetylation was specifically abrogated in p53117R/117R
MEFs, whereas acetylation of the other sites remained normal
(Figure 6D, lane 5). Moreover, ChIP assays revealed that both
WT p53 and p53-3KR proteins bind equally well to the promoters
of the GLS2 and TIGAR metabolic target genes. Thus, although
p533KR fails to transactivate most p53 target genes, including
those involved in p53-mediated cell-cycle arrest, apoptosis,
and senescence, it retains the ability to induce the metabolic
target genes GLS2 and TIGAR in response to stress. Finally,
increased glucose uptake is a common characteristic of tumor
cells that preferentially metabolize glucose by aerobic glycolysis
instead of oxidative phosphorylation, and several studies have
shown that p53 expression leads to transcriptional downregu-
lation of the GLUT3 (Kawauchi et al., 2008; Schwartzenberg-
Bar-Yoseph et al., 2004). As expected, GLUT3 expression is
dramatically increased in p53/ cells relative to WT MEFs (Fig-
ure 6F). Significantly, the levels of GLUT3 transcript remain low in
p533KR/3KR cells, suggesting that p533KR can inhibit GLUT3
expression in a manner similar to WT p53 (Figure 6F). Together,
these data demonstrate that p533KR retains the capacity to regu-
late the expression of multiple metabolic p53 target genes.
The Inhibitory Effects of p533KR in Regulating Glucose
Uptake, Glycolysis, ROS, and Colony Formation
Cancer cells consume large quantities of glucose for glycolysis.
It has been reported that inactivation of p53 leads to high
glucose uptake (Zhang et al., 2011). Because p53-3KR is able
to inhibit the expression of GLUT3, p533KR/3KR cells are likely
to retain the ability to suppress glucose uptake. To confirm this
prediction, we compared uptake of 2-[3H]deoxyglucose in
p53+/+, p533KR/3KR, and p53/ MEFs. As shown in Figure 7A,
relative glucose uptake was approximately 3-fold higher in
p53/ MEFs than p53+/+ MEFs, validating that p53 loss signifi-
cantly promotes glucose uptake (Zhang et al., 2011). In contrast
we failed to detect a significant increase in p533KR/3KR MEF cells,
suggesting that p533KR retains the ability to suppress glucose
uptake normally. Moreover, we compared the glycolysis rate
in p53+/+, p533KR/3KR, and p53/ MEFs by monitoring the
conversion of 5-[3H]glucose to 3H2O, as described previously
by Ashcroft et al. (1972). As shown in Figure 7B, the glycolysis
rate of p53/ MEF cells was about 60% higher than that of
WT MEFs, indicating that p53 loss indeed increases the rate of
glycolysis in vivo. In contrast the glycolysis rate of p533KR/3KR
cells was very similar to that observed in WT MEFs. Thus,
p533KR retains the ability to suppress both glucose uptake
and glycolysis.
ROS are produced as a normal by-product of cellular metab-
olism and function as signaling molecules involved in tumorigen-
esis. Previous studies indicate that both GLS2 and TIGARCell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc. 1277
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for 8 hr. Data are averages ± SEM of each mRNA quantities normalized first to b-actin and then to the untreated WT sample values from three independent
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with 0.2 mg/ml Dox for 8 hr. b-actin serves as a loading control.
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Figure 7. p533KR Inhibits Glucose Uptake,
Glycolysis, ROS Level, and Colony Forma-
tion
(A) Glucose uptake measurement of p53+/+,
p533KR/3KR, and p53/ MEF cells determined by
the uptake of 2-[3H]deoxyglucose. Results shown
are the averages ± SD of three different experi-
ments.
(B) Glycolysis rate analysis of p53+/+, p533KR/3KR,
and p53/MEF cells determined bymonitoring the
conversion of 5-[3H]glucose to 3H2O as described
in the Experimental Procedures. Values represent
averages ± SD of three different experiments.
(C) Measurement of the ROS levels of p53+/+,
p533KR/3KR, and p53/ MEF cells was performed
by using mouse ROS ELISA kit as described in the
Experimental Procedures. Data are reported as
averages ± SD of three different experiments.
(D) Western blot (WB) analysis of p53-3KR, Mdm2,
and Gls2 proteins in H1299 cells transfected with
FLAG-tagged expression plasmids as indicated
using anti-FLAG antibody. b-actin was used as
a loading control.
(E) Colony-formation assay of H1299 cells trans-
fected with p53-3KR, Mdm2, and Gls2. H1299 cells
were transfected with empty vector, or FLAG-p53-
3KR, FLAG-Mdm2, or FLAG-Gls2 expression
plasmids for 48 hr, and then split and subjected to
colony-formation assay visualized by crystal violet
staining.
(F) Quantification of colonies formed in H1299 cells
transfected with empty vector, FLAG-p53-3KR,
FLAG-Mdm2, and FLAG-Gls2 expression plasmids
after 12 day culture in the presence of G418.
Graphs are presented as percentage of colonies of
empty vector-transfected cells, and values are
shown as average percentage ±SD of three
different experiments.regulate the levels of ROS in cancer cells (Bensaad et al., 2006;
Hu et al., 2010; Suzuki et al., 2010). Thus, we compared the
levels of ROS in p53+/+, p533KR/3KR, and p53/MEFs. As shown
in Figure 7C, the ROS levels of p53/ MEFs were about 85%
higher than those of WT cells, suggesting that p53 loss signifi-(E) ChIP assay for the binding of p53 or p53-3KR mutant to the consensus sites of p53 metabolic targets Gls
DNA-expressing mouse p53 WT or p53-3KR mutant.
(F) RT-PCR (upper panel) and quantitative real-time PCR (lower panel) analysis ofGlut3 expression in p53+/+,
Data are represented as averages ± SEM from three independent experiments.
See also Figure S7.
Cell 149, 1269–1cantly increases ROS levels in vivo.
Conversely, the ROS levels of p533KR/3KR
MEF cells were indistinguishable from
those of WT cells. Finally, we tested
whether expression of p53-3KR is able to
suppress colony formation of cancer cells
in a manner analogous to GSL2 expres-
sion, as reported by Hu et al. (2010) and
Suzuki et al. (2010). To this end, p53 null
H1299 cells were transfected for 48 hr
with an empty expression vector, Flag-GLS2 expression vector alone, or Flag-p53-3KR expression
vector and Flag-Mdm2 expression vector (Figure 7D). As shown
in Figures 7E and 7F, p53-3KR expression significantly reduced
colony formation. Notably, in contrast to GLS2 expression,
Mdm2 expression in these p53 null cells had no obvious effect,2 and Tigar in H1299 cells transfected with plasmid
p533KR/3KR, and p53/ primary MEFs at passage 2.
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suggesting that Mdm2 induction by p53-3KRmay not contribute
to its tumor suppression activity (Figure 7E). Together, these
data suggest that p53-3KR retains its tumor suppressor activity,
at least in part, through its ability to regulate energy metabolism
and ROS levels in vivo.
DISCUSSION
Because p53 mutations are the most common genetic lesions
associated with human cancer, a major objective of molecular
oncology is to elucidate the mechanisms by which p53
suppresses tumor formation. Our studies of mice expressing
acetylation-defective p53 mutants revealed that acetylation
differentially regulates p53 function in cell-cycle arrest,
apoptosis, and senescence. This circumstance afforded us the
opportunity to test whether these p53 functions are required
for p53-mediated tumor suppression. Surprisingly, we found
that the combined loss of p53-dependent cell-cycle arrest,
apoptosis, and senescence is not sufficient to abrogate the
tumor suppression activity of p53. By demonstrating that the
canonical functions of p53 in cell-cycle arrest, apoptosis, and
senescence are not absolutely required for tumor suppression,
these results challenge the prevailing view of how p53 lesions
promote human cancer.
Reassessing the Mechanisms of p53-Mediated Tumor
Suppression
Through its ability to induce cell-cycle arrest, apoptosis, or
senescence in response to various types of stress, p53 is
thought to suppress tumor formation by preventing inappro-
priate expansion of cells with malignant potential. Although non-
transcriptional functions of p53 may also contribute to tumor
suppression, recent studies of mice bearing defined mutations
of the p53 transactivation domains indicate that its role as a tran-
scription factor is essential for p53-mediated tumor suppression
(Brady et al., 2011).
The ability of p53 to induce cell-cycle arrest is mediated in
large part by transcriptional activation of p21Cip1, which encodes
an inhibitor of cyclin-dependent kinases (el-Deiry et al., 1993).
The induction of p21 expression is sensitive to even low levels
of p53 protein, suggesting that a temporary G1 or G2 block, as
induced by mild damage or stress, allows cells to survive until
damage has been resolved or stress removed. In addition, p21
is also critical for p53-dependent senescence—an irreversible
cell-cycle arrest that can be elicited by DNA damage, oncogene
activation, or telomere dysfunction. However, unlike p53 null
mice, p21 null animals are not prone to early-onset tumorigen-
esis, although p21 deficiency extends longevity and rescues
stem cell function in mice with dysfunctional telomeres (Deng
et al., 1995; Choudhury et al., 2007). This observation implies
that the apoptotic functions of p53 may be more relevant to
tumor suppression, or may contribute to tumor suppression in
a compensatory fashion when p53-mediated cell-cycle arrest
and/or senescence is compromised. Nevertheless, early-onset
tumor formation is not observed in mice expressing an
apoptosis-defective mutant (p53R172P) that retains the cell-cycle
arrest and cellular senescence functions of p53 (Liu et al., 2004;
Cosme-Blanco et al., 2007;Van Nguyen et al., 2007). Likewise,1280 Cell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc.mice lacking PUMA, a p53-target gene required for p53-depen-
dent apoptosis in a broad range of cell types (Yu and Zhang,
2008), are still resistant to early-onset tumorigenesis (Michalak
et al., 2008). Interestingly, a p53 mutant (p5325,26) deficient for
p53-mediated cell-cycle arrest and apoptosis, but not senes-
cence, was recently shown to retain the ability to inhibit
KrasG12D-induced lung carcinogenesis (Brady et al., 2011).
Thus, despite the fact that the canonical functions of p53 in
cell-cycle arrest, apoptosis, and senescence are widely
accepted as the major mechanisms of p53-mediated tumor
suppression, it has never been formally tested whether they
are the rate-limiting steps in vivo.
Numerous studies suggest that cell-cycle arrest, apoptosis,
and senescence are crucial for p53-mediated tumor suppres-
sion. Nonetheless, it is unclear why these aspects of p53
function are required for tumor suppression only under certain
biological settings. For example PUMA is a critical target for
p53-mediated apoptosis, but PUMA knockout mice fail to
develop early-onset spontaneous tumors. Yet, loss of PUMA
apparently accelerates Em-Myc-mediated lymphomagenesis
(Garrison et al., 2008; Michalak et al., 2009). Likewise, p53-medi-
ated senescence is apparently critically involved in suppressing
KrasG12D-induced lung carcinogenesis (Brady et al., 2011). It is
possible that p53 can suppress tumor formation with distinct
mechanisms under different physiological settings. Moreover,
because p53 lesions are observed in a broad spectrum of human
cancers, it will be interesting to ascertain whether these aspects
of p53 function are differentially required for tumor suppression
in different types of cancers. Clearly, our studies demonstrate
that p53-mediated cell-cycle arrest, apoptosis, and senescence
are not essential for suppressing early-onset spontaneous
tumorigenesis, which raises a fundamental question regarding
whether these well-studied activities of p53 are truly the most
important functions of tumor suppression in general.
A Role for p53-Mediated Metabolic Regulation in Tumor
Suppression?
Although p53-mediated cell-cycle arrest, apoptosis, and senes-
cence are presumed to be the primary mechanisms by which
p53 inhibits oncogenesis, the phenotype of p533KR/3KR mice
indicates that other, as yet undetermined, functions of p53 are
also important for tumor suppression. In principle the relevant
aspects of p53 function should be retained by the p533KRmutant
polypeptide. As such, it is intriguing that p533KR, which fails to
transactivate a number of genes involved in p53-mediated cell-
cycle arrest, apoptosis, and senescence, still maintains the
capacity to regulate p53 target genes implicated in metabolic
control, including GLS2, TIGAR, and GLUT3. In resting cells
under normal aerobic conditions, the pyruvate generated by
glycolysis can be fed into the mitochondrial tricarboxylic acid
(TCA) cycle for efficient ATP generation via oxidative phosphor-
ylation. However, proliferating cells undergo ametabolic reprog-
ramming to ‘‘aerobic glycolysis’’ in which glycolytic flux is
increased, oxidative phosphorylation is suppressed, pyruvate
is converted primarily to lactate, and intermediates of the TCA
cycle are diverted into anabolic pathways to facilitate cell growth
(Vander Heiden et al., 2009). A similar metabolic switch to
aerobic glycolysis, termed the Warburg effect, is also observed
in tumor cells, and recent studies suggest that p53 normally
inhibits this process by limiting glycolytic flux through multiple
mechanisms (Gottlieb and Vousden, 2010; Feng and Levine,
2010; Warburg, 1956). For example p53 suppresses the expres-
sion of glucose transporters such as GLUT3 (Kawauchi et al.,
2008; Schwartzenberg-Bar-Yoseph et al., 2004), although the
precise mechanism of this repression needs further elucidation.
p53 also modulates production of glutamine, an alternative to
glucose as a fuel for bioenergetic pathways, by transactivating
the gene for GLS2, a mitochondrial glutaminase that converts
glutamine to glutamate (Hu et al., 2010; Suzuki et al., 2010). As
such, GLS2 promotes energy metabolism by providing a source
of a-ketoglutarate for the TCA cycle and antioxidant defense by
providing glutamate for glutathione synthesis. Notably, GLS2 is
downregulated in human cancer, and GLS2 overexpression
reduces the in vitro proliferation and colony-forming potential
of tumor cells (Hu et al., 2010; Suzuki et al., 2010). The gene
encoding TIGAR was also identified as a key p53 target impli-
cated in energy metabolism and ATP generation (Bensaad
et al., 2006). By lowering levels of fructose-2, 6,-bisphosphate,
TIGAR normally functions to reduce glycolytic flux and direct
glucose to the pentose phosphate pathway. Thus, p53 inactiva-
tion promotes metabolic changes similar to the Warburg effect
by increasing both glycolytic flux and lactate production (Got-
tlieb and Vousden, 2010; Feng and Levine, 2010).
Although cell-cycle arrest, senescence, and apoptosis are
abrogated in p533KR/3KR cells, p533KR retains its ability to
suppress glucose uptake and glycolysis. Moreover, consistent
with the fact that both GLS2 and TIGAR are critically involved
in regulating ROS in vivo, p533KR retains its capacity to reduce
ROS levels, and expression of p533KR leads to suppression of
colony-formation ability of cancer cells. In light of these results,
p533KR may block tumor formation, at least in part, by inhibiting
themetabolic shift to aerobic glycolysis and reducing ROS levels
in vivo. As such, the ability of p53 to regulate the metabolic state
and antioxidant defense may serve as independent mechanisms
of tumor suppression that are sufficient to suppress early-onset
spontaneous tumorigenesis when the p53-mediated pathways
of cell-cycle arrest, apoptosis, and senescence are simulta-
neously inoperative. Clearly, the molecular mechanisms by
which p53 regulates its metabolic target genes need further
elucidation. Based on our studies, the requirements for acti-
vating p53-mediated metabolic regulation are apparently
different from those that modulate cell-cycle arrest, apoptosis,
and senescence. It will be interesting to know whether other
recognized acetylation sites, such as C terminus lysine residues
and K320, or other types of p53 modification, such as phosphor-
ylation or methylation, modulate the expression of these meta-
bolic targets of p53 in vivo.
EXPERIMENTAL PROCEDURES
Generation and Characterization of Mice
To generate knockin mice, W4/129S6 mouse ES cells (Taconic, Hudson, NY,
USA) were electroporated with targeting vectors containing 50 homology
region with exons 1–4, a neo cassette flanked by two LoxP sites (LNL), and
a 30 homology region with exons 5–11 with the desired point mutations. ES
cells were selected by G418 and screened for homologous recombination
by Southern blotting with BglII-digested genomic DNA using standard proto-cols. Southern blot probes were generated from PCR amplification in the
regions outside the targeting vector. The correctly targeted ES clones contain-
ing the targeted allele with desired mutation(s) were injected into C57BL/6
blastocysts, which were then implanted into pseudopregnant females to
generate chimeras. Germline transmission was confirmed by breeding
chimeras with C57BL/6 mice. Germline-transmitted mice were bred with
Rosa26Cre mice to remove the LNL cassette and generate mice with only
the targeted p53K117R or p533KR mutations. To further validate the mutations
created in p53K117R/K117R or p533KR/3Kr mice, we sequenced p53 mRNA from
MEFs derived from these mice, and only the desired point mutations and no
additional mutations were found. The offspring were PCR genotyped using
a primer set (forward, 50-CTTCCTGCAGTCTGGGACAGC C-30; reverse,
50-GCAGCTGGGCCTACAGCACACG-30 ). All animal experiments were
approved by the IACUC (Institutional Animal Care and Use Committee) at
Columbia University Health Sciences Center under the supervision of the Insti-
tute of Comparative Medicine.
Protein Purification and Mass Spectrometry
To purify the acetylated mouse p53 protein, H1299 cells were cotransfected
with pCin4-p53-Flag and CMV-Tip60 and cultured for 20 hr, then the trans-
fected H1299 cells were treated with 1 mM TSA and 5 mM nicotinamide for
6 hr before harvest. Cells were collected and lysed in the Flag-lysis buffer
(50 mM Tris-HCl [pH 7.9], 137 mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton
X-100, 0.2% sarkosyl, 10% glycerol, and fresh proteinase inhibitor cocktail
[Sigma-Aldrich]) plus 2 mM TSA and 10 mM nicotinamide, and the cell extracts
were immunoprecipitated with the anti-Flag monoclonal antibody-conjugated
M2 agarose beads (Sigma-Aldrich). The Flag peptide-eluted material was
resolved by 8% SDS-PAGE. The p53 bands were excised from the gel and
subjected to tryptic digestion and mass spectrometry.
Colony Formation Assay
H1299 cells were transfected with either empty vector or FLAG-tagged-
p53, -GLS2, and -Mdm2 expression plasmids for 48 hr. Cells were then split
and seeded into 10 cm dishes at the density of 1,000 cells per dish and
cultured under the selection of G418 (600 mg/ml) for 12 days. Cells were
stained with crystal violet solution, and visible colonies were counted.
Measurement of Glucose Uptake and Glycolysis Rate
Glucose uptake of p53+/+, p533KR/3KR, and p53/MEF cells wasmeasured by
determining the uptake of 2-[3H]deoxyglucose (American Radiolabeled Chem-
icals) by MEF cells as previously described by Zhang et al. (2011). Briefly, MEF
cells were seeded in triplicate at 2.5 3 105 cells per well in 6-well plates. After
incubation at 37C overnight, the cells were washed twice with Krebs buffer
(116 mM NaCl, 4.6 mM KCl, 1.16 mM KH2PO4, 25 mM NaHCO3, 2.5 mM
CaCl2$2H2O, 1.16 mM MgSO4$7H2O, 0.2% bovine serum albumin [pH 7.4]).
Then, 1 ml Krebs buffer was added to each well, and the cells were incubated
at 37C for 30 min, and then another 1 ml Krebs buffer containing 2 mCi/ml [3H]
2-deoxy-D-glucose was added to each well. Cells treated with 20 mM glucose
transport inhibitor cytochalasin B (Sigma-Aldrich) were used as a negative
control. Cells were incubated at 37C for 20 min and then washed four times
with ice-cold Krebs buffer, and lysed with 0.5 ml 1% SDS. 2-[3H]deoxyglucose
was quantified by scintillation counting. Glycolysis rate of p53+/+, p533KR/3KR,
and p53/ MEF cells was determined by monitoring the conversion of 5-[3H]
glucose to 3H2O as described previously by Ashcroft et al. (1972). To measure
glycolysis rate, 2.5 3 105 MEFs were seeded in each well of 6-well plates and
cultured overnight. MEF cells were washed once with PBS and once with
Krebs buffer, and 1 ml of Krebs buffer was added to cells. After the cells
were incubated for 30 min at 37C, 0.5 ml of Krebs buffer containing 10 mM
glucose and 10 mCi of 5-[3H]glucose was added. Following incubation for
1 hr at 37C, 500 ml of 0.2 N HCl was added to the cells to stop the reaction,
then scrape the cells, and 500 ml cell suspension aliquots in triplicate were
transferred to uncapped 1.5ml Eppendorf tubes that then were put into a scin-
tillation vial containing 1.0 ml of H2O in such a way that the water in the vial and
the contents of the 1.5 ml Eppendorf tube were not allowed to mix. The vials
were sealed, and diffusion was allowed to occur for a minimum of 24 hr at
room temperature. The amounts of diffused 3H2O in the vial, representing
the glycolysis rate, were determined by scintillation counting.Cell 149, 1269–1283, June 8, 2012 ª2012 Elsevier Inc. 1281
Measurement of ROS
A total of 53 105 p53+/+ and p533KR/3KR and p53/MEFswere seeded in 6 cm
dishes, following incubation at 37C overnight, the cells were collected and
lysed for ROS assay using Mouse Reactive Oxygen Species ELISA kit
(E03R0070) from Life Science Advanced Technologies. Briefly, 100 ml of
samples or standards with known concentration of ROS was added to the
triplicate microtiter plate wells precoated with anti-ROS antibody, and then
50 ml ROS-HRP conjugate was added to each well, mix and incubate microtiter
plate at 37C for 1 hr, then the wells were washed with 400 ml 13 washing
solution for five times and incubated for 15minwith addition of 50 ml substrates
for HRP enzyme. The enzyme-substrate reaction was terminated by adding
50 ml of stop solution to each well, and the optical density (OD) at a wavelength
of 450 nm was measured immediately using mQuant Scanning Microplate
Spectrophotometer (BioTek Instruments). The concentration of ROS in each
sample was then determined by comparing the OD of each sample to the
standard curve.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/
j.cell.2012.04.026.
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